The treatment of myelin oligodendrocyte glycoprotein antibody disease: a state-of-the-art review
Journal: Journal of Neuro-Ophthalmology; September 1, 2022
Author(s): Bart K. Chwalisz and Michael Levy
Acute and long-term treatment of MOGAD
This study reviews previously published studies on acute treatment of MOGAD with corticosteroids and adjunct therapies, such as intravenous immunoglobulin (IVIG) and plasma exchange; discusses the value of prolonged corticosteroid tapering after acute attacks; and summarizes the long-term therapies available for MOGAD, including chronic low-dose corticosteroids, classic antirheumatic immune suppressants, biologic agents, and IVIG. While acute MOGAD attacks are usually treated with high-dose IV corticosteroids, longer oral corticosteroid tapers may prevent rapid relapse. Multiple long-term treatment strategies are being used for recurrent MOGAD, with IVIG emerging as probably the most effective therapy.
Free Access: Full text
